Disease	Advanced cancer/solid tumor only
Stage of Disease/Treatment	Metastatic/advanced
Prior Therapy	No designated number of regimens
Type of Study	Phase I, dose escalation + dose exploration
Primary Endpoint	Safety, tolerability
Secondary Endpoints	Maximum tolerated dose, recommended phase II dose, pharmacodynamics, other
Additional Details of Endpoints or Study Design	The study included dose escalation and dose exploration. For the dose escalation, a modified 3+3 design was used, with dose‐limiting toxicity (DLT) evaluated up to 28 days after the first dose. Eight dose levels were evaluated. The first three dose levels were assessed in single‐patient cohorts. If a grade ≥2 drug‐related adverse event (AE) was observed during the DLT period, two additional patients were enrolled and administered the same dose. For the remaining dose levels, a standard 3+3 design was followed. In the dose exploration, patients received envafolimab 300 mg SC once every 4 weeks (Q4W).
Investigator's Analysis	Active and should be pursued further